You are here

Home » Library » Topic Index » HIV Continuum of Care » Step 1: Preventing New Infections » Pre-exposure Prophylaxis

Pre-exposure Prophylaxis

Active Resources: 23

Toolkits

Pocket Guides

Online and Self-Paced Learning

Clinical Reference Tools

Prevention & Testing Guidelines (PEP, PrEP, PWP)

Webinar Recordings

Curricula

Online Training

Reports

Primary Care Guidelines

Charts, Tables & Posters

Coinfection Guidelines (Hep, TB, STIs)

Slide Sets

Articles: 5

  • AETCs at the 2018 Ryan White Conference

    Judy Collins's picture

    November 26, 2018

    The AETC Program will be well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. Additionally, the AETC National Coordinating Resource Center will be exhibiting an array of AETC Program developed resources and promotional items at Booth #12 in...

  • U=U in PARTNER2 Study of MSM

    Susa Coffey's picture

    August 21, 2018

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).

    PARTNER1 evaluated HIV transmission risk in a European...

  • HIV Meds Update: PrEP Uptake by Sex, Race, and Age

    Susa Coffey's picture

    September 27, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...

  • PrEP: Bone Density Improves after Stopping TDF/FTC

    Susa Coffey's picture

    May 4, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender women...

  • Tissue Levels of TAF: Too Low for PrEP?

    Susa Coffey's picture

    March 17, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir...